Serum glycan as a prognostic marker in patients with advanced hepatocellular carcinoma treated with sorafenib

Hepatology

Volumn 59, Issue 1, 2014, Pages 355-356

  Miyahara, Koji ^a   Nouso, Kazuhiro ^a   Miyake, Yasuhiro ^a   Nakamura, Shinichiro ^a   Obi, Shuntaro ^b   Amano, Maho ^c,d   Hirose, Kazuko ^c   Nishimura, Shin Ichiro ^c,d   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Kyoundo Hospital   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d Hokkaido University and Medicinal Chemistry Pharmaceuticals LLC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; N GLYCAN; SORAFENIB; UNCLASSIFIED DRUG; POLYSACCHARIDE; TUMOR MARKER;

ADVANCED CANCER; BLOOD LEVEL; CANCER PROGNOSIS; CHILD PUGH SCORE; CHRONIC HEPATITIS; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER RESECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; BLOOD; FEMALE; GLYCOBIOLOGY; LIVER TUMOR; MALE; NOTE;

CARCINOMA, HEPATOCELLULAR; FEMALE; GLYCOMICS; HUMANS; LIVER NEOPLASMS; MALE; POLYSACCHARIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84894794252     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26531     Document Type: Letter

References (2)

1. Kamiyama T, Yokoo H, Furukawa JI, Kurogochi M, Togashi T, Miura N, et al. Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. Hepatology 2013 [Epub ahead of print].
2. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J; SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-2300.